Upgrade to SI Premium - Free Trial

Ocugen (OCGN)

1.00 -0.06 (5.66%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/10/26)

Latest Headlines

Form 4 Ocugen, Inc. For: Sep 09 Filed by: Musunuri Shankar September 11, 2026 9:14 PM - SEC Filing Ocugen, Inc. (OCGN) PT Lowered to $9.50 at H.C. Wainwright September 10, 2026 6:52 AM - StreetInsider Ocugen doses first patient in Phase 3 gene therapy trial for dry AMD September 1, 2026 7:02 AM - StreetInsider Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration September 1, 2026 7:02 AM - StreetInsider Ocugen to Participate in Upcoming September Investor and Industry Conferences August 25, 2026 7:02 AM - StreetInsider Form DEFA14A Ocugen, Inc. August 14, 2026 6:10 AM - SEC Filing Form SCHEDULE 13G/A Ocugen, Inc. Filed by: Janus Henderson Group Ltd. August 13, 2026 12:42 PM - SEC Filing Form SCHEDULE 13G Ocugen, Inc. Filed by: STATE STREET CORP August 7, 2026 10:29 AM - SEC Filing Form 10-Q Ocugen, Inc. For: Jun 30 August 6, 2026 12:16 PM - SEC Filing Form 8-K Ocugen, Inc. For: Aug 06 August 6, 2026 8:31 AM - SEC Filing Ocugen (OCGN) Misses Q2 EPS by 2c August 6, 2026 7:53 AM - StreetInsider Ocugen Provides Business Update with Second Quarter 2026 Financial Results August 6, 2026 7:02 AM - StreetInsider Ocugen to Participate in Upcoming August Investor Conferences July 31, 2026 7:02 AM - StreetInsider Form DEFA14A Ocugen, Inc. July 30, 2026 4:37 PM - SEC Filing Form DEF 14A Ocugen, Inc. For: Sep 21 July 30, 2026 4:31 PM - SEC Filing Form SCHEDULE 13G Ocugen, Inc. Filed by: BlackRock, Inc. July 29, 2026 3:21 PM - SEC Filing FDA grants RMAT designation to Ocugen's OCU410 for dry AMD July 29, 2026 7:03 AM - StreetInsider Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Relat July 29, 2026 7:01 AM - StreetInsider Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results July 28, 2026 4:01 PM - StreetInsider Form PRE 14A Ocugen, Inc. For: Sep 21 July 20, 2026 5:01 PM - SEC Filing Form 8-K Ocugen, Inc. For: Jul 13 July 13, 2026 8:31 AM - SEC Filing Ocugen signs MENA licensing deal for OCU400 gene therapy July 13, 2026 7:03 AM - StreetInsider Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa July 13, 2026 7:02 AM - StreetInsider Ocugen to Participate in Upcoming July Industry Conferences July 1, 2026 7:00 AM - StreetInsider Form 4 Ocugen, Inc. For: Jun 15 Filed by: Johnson-Greene Treerita Essalima June 17, 2026 4:14 PM - SEC Filing Full Article List